#hf-patient-journey #header h1 { margin-top: 10px; color: #fff; } #hf-patient-journey #section-1 .dn-btn { display: block; width: 100%; text-align: center; }
What the 2022 ADA Consensus recommends for
Screening & Diagnosis of Heart Failure in Pre-Diabetic and Diabetic Patients
The burden of CVD in Diabetic Patients in APAC
Prevalence of Cardiovascular Disease (CVD) among Type 2 diabetes mellitus (T2DM) patients1
T2DM is associated with a twofold increased risk of CVD vs non-T2DM patients1
Pre-Diabetic and Diabetic Patients at risk of Heart Failure
STAGE A
High risk for HF
- Obesity
- Hypertension
- Hyperlipidemia
- Diabetic Kidney Disease
- Coronary Artery Disease
- Sex
- Social Determinants of Health
- Duration of Diabetes
- Uncontrolled Hypertension
STAGE B
Cardiac Structural Abnormality/ Dysfunction
- LV systolic dysfunction
- LV diastolic dysfunction
- LV hypertrophy
- Chamber enlargement
- Valvular disease
- Increased filling pressures OR Elevated biomarkers
Biomarkers
- NT-proBNP (≥125 pg/mL)
- BNP (≥50 pg/mL)
- High Sensitive Cardiac Troponin
(>99th per-centile upper reference limit)
Normal
Elevated
Repeat
in at least 1 year
Imaging
(CXR, Echocardiogram)
